Study: Day 2025, Frontiers in Allergy

Risk factors for angiotensin converting enzyme inhibitor angioedema in a South African population

Citation

Day C, Mapahla L, Ribeiro M, Deetlefs M et al (2025). Frontiers in Allergy. PubMed id 41189626.

Open on PubMed

Cards that cite this study (1)

Each card gives its own wording for who was tested, how and what was found.

  • How some medicines work differently by gene Tier B moderate

    B 237 people with ACE inhibitor angioedema and 466 drug-tolerant controls in Cape Town, South Africa (n=703)

    Case-control cohort study.

    Cases more often had Black genetic ancestry than controls (53% against 29%, P under 0.001). Only 31.1% of angioedema occurred within 30 days of starting, and the median time to angioedema was 6.9 years, so it can start long after starting treatment. The authors describe ACE inhibitors as having proven mortality and morbidity benefit.

    As recorded in this card: Day C, Mapahla L, Ribeiro M, Deetlefs M et al (2025), Frontiers in Allergy, [primary]

    Note: South African data (an African setting, not US); the abstract was cut off before the full risk-factor list.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.